Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Incyte (INCY) PT Raised to $87 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Andrew S. Berens raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This morning, Incyte reported 3Q24 financial results and provided updates on the pipeline. INCY beat consensus on key product revenues, with... More
Incyte (INCY) PT Raised to $97 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Incyte (NASDAQ: INCY) to $97.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Incyte reported 3Q24 results, delivering topline revenue beats due to sustained growth for key franchise drivers in Jakafi and... More
Incyte (INCY) PT Raised to $84 at Jefferies
October 29, 2024 2:41 PM EDTJefferies analyst Kelly Shi raised the price target on Incyte (NASDAQ: INCY) to $84.00 (from $81.00) while maintaining a Buy rating.
The analyst comments "INCY delivered great Q with rev beat ($1.14B vs $1.08B cons) all around - Jakafi $741M (+5% QoQ vs $718M cons) and... More
